Triochem Products Share Price Today | Stock Price & Triochem Products Share Screener
Track the current Triochem Products share price and stock price live with TickJournal's free stock screener. Check TRIPR 52-week chart for the annual price range and momentum. Use the Triochem Products stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Triochem Products opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹12 and net income of ₹8, with EBITDA of ₹11.
Triochem Products Share Price Chart
Track the current stock price of Triochem Products with an interactive chart. Analyse TRIPR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Triochem Products stock quote in one place.
Triochem Products Company Profile - Fundamental Screener
Screen Triochem Products company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for TRIPR shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE331E01013.
Company Details
Classification
Identifiers and Leadership
Triochem Products Balance Sheet Screener
Screen TRIPR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹21, up from ₹14 in 2025.
Latest statistics put total assets at ₹21 and shareholder funds at ₹21.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 21 | 14 | 15 | 12 | 13 | 12 | 17 | 15 | 12 | 10 |
| Current Assets | 13 | 3 | 3 | 1 | 12 | 11 | 15 | 14 | 10 | 8 |
| Fixed Assets | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 21 | 14 | 15 | 12 | 13 | 12 | 12 | 9 | 8 | 6 |
| Share Capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves & Surplus | 20 | 13 | 14 | 11 | 13 | 12 | 12 | 9 | 8 | 5 |
Triochem Products Income Statement Screener - Profit & Revenue Analysis
Screen Triochem Products income statement and profit fundamentals. Analyze TRIPR quarterly results. Triochem Products reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹12 and net profit was ₹8, equal to earnings per unit of ₹330.50.
In that period expenses were ₹1, interest cost ₹0 and tax ₹2. The next period listed, 2026-March, shows revenue of ₹1 and net profit of ₹8.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 12 | 1 | 1 | 1 | 0 | 9 | 14 | 21 | 12 | 35 | 18 | 23 | 31 |
| Expenses | 1 | 1 | 1 | 1 | 1 | 8 | 14 | 16 | 11 | 31 | 17 | 22 | 30 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 11 | -1 | 0 | 0 | -1 | 2 | 0 | 5 | 2 | 4 | 1 | 1 | 1 |
| Operating Profit % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 15.00% | -3.00% | 22.00% | 13.00% | 11.00% | 5.00% | 4.00% | 4.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 11 | 11 | 0 | -1 | -1 | 2 | -1 | 5 | 1 | 4 | 1 | 1 | 1 |
| Tax | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Net Profit | 8 | 8 | 0 | -1 | -1 | 1 | 0 | 3 | 1 | 3 | 1 | 0 | 0 |
| EPS | 330.50 | 325.34 | -16.33 | -41.36 | -36.12 | 53.99 | -18.24 | 138.89 | 30.33 | 104.29 | 23.51 | 13.94 | 16.98 |
Triochem Products Cash Flow Screener - Liquidity Fundamentals
Screen TRIPR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹3, and net cash flow was an inflow of ₹11.
Over the same period, investing activities provided ₹14 and financing activities provided ₹0.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -3 | 0 | -4 | -1 | 4 | 10 | 4 | -4 | 2 | -7 |
| Investing Activities | 14 | 0 | 3 | -10 | 0 | 0 | 0 | 0 | 0 | 4 |
Financing and Net Cash | ||||||||||
| Financing Activities | 0 | 0 | 0 | 0 | 0 | -3 | -4 | 3 | -1 | 3 |
| Net Cash Flow | 11 | 0 | 0 | -11 | 4 | 8 | 0 | -1 | 1 | 0 |
Triochem Products Shareholding Pattern Screener
See Triochem Products shareholding pattern with promoter, FII, and DII holdings. Check Triochem Products promoter holding and ownership changes for TRIPR on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 68.65%, foreign institutions 0.00%, domestic institutions 0.00% and the public 15.53%, spread across 54 shareholders.
The shareholder count was 54 in 2026-Mar, compared with 55 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 15.53% | 15.53% | 15.53% | 15.53% | 15.53% | 15.53% | 15.53% | 15.53% |
| Other Holding | 15.82% | 15.82% | 15.82% | 15.82% | 15.82% | 15.82% | 15.82% | 15.82% |
| Shareholder Count | 54 | 55 | 55 | 55 | 55 | 54 | 55 | 55 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Triochem Products. Triochem Products dividend yield can be compared with peers and other stocks in the market.
Triochem Products Stock Index Membership - Nifty & Sensex
See which indices include Triochem Products stock. Check TRIPR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Triochem Products Market Events Screener - Corporate Actions
Get Triochem Products corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Triochem Products stock events that may affect TRIPR share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Annual General Meeting dated August 22, 2026, with a record date of August 22, 2026.
It is followed by Quarterly Result Announcement dated August 14, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-22 | 2026-08-22 | Annual General Meeting | NA | - |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | - |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | - |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | - |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | - |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | - |
| 2025-06-25 | 2025-06-25 | Annual General Meeting | NA | - |
| 2025-05-24 | 2025-05-24 | Quarterly Result Announcement | NA | - |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | - |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | - |
| 2024-08-22 | 2024-08-22 | Annual General Meeting | NA | - |
Triochem Products Competitors Screener - Peer Stocks Comparison
Screen TRIPR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Triochem Products Company Announcements - News & Reports Screener
Screen TRIPR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated August 24, 2026 and August 24, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Closure of Trading Window | - |
| 2026-08-24 | Announcement under Regulation 30 (LODR)-Meeting Updates | - |
| 2026-08-24 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-22 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32(1) Of The SEBI (Listing Obligation & Disclosures Requirement) Regulation 2015 For The Quarter Ended 30Th June 2026. | - |
| 2026-08-14 | Submission Of Unaudited Standalone Financial Results For The Quarter Ended 30Th June 2026 | - |
| 2026-08-14 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday 14Th August 2026 | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-08 | Board Meeting Intimation for Intimation Of Board Meeting For The Quarter Ended 30Th June 2026 Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-30 | Reg. 34 (1) Annual Report. | - |
| 2026-07-30 | Notice Of Fifty-Four Annual General Meeting (AGM) Of The Company Will Be Held On Saturday 22Nd August 2026 | - |
| 2026-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-15 | Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount For Loans Including Revolving Facilities Like Cash Credit From Banks / Financial Institutions | - |
| 2026-07-15 | Quarterly Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount On Loans From Banks / Financial Institutions And Unlisted Debt Securities | - |
| 2026-07-15 | Compliance-57 (5) : intimation after the end of quarter | - |
| 2026-06-30 | Compliance-57 (4) : Prior intimation to the beginning of the quarter | - |
| 2026-06-30 | Closure of Trading Window | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
Frequently Asked Questions
How is the company valued right now?
The P/E ratio is 15.00 and the P/B ratio is 0.04, with earnings per unit of ₹325.34. Market capitalisation stands at ₹0.40 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.